The KN406 antibody is protected by ZIF‐8 in normal tissue but released in tumors to block the binding of PD‐L1 to PD‐1 and CTLA‐4 to CD80/CD86, thereby effectively enhancing the killing of tumor cells (Figure 1b). This evidence concerns the gene CTLA4 and neoplasm.